Literature DB >> 6295193

Hepatoblastoma. Attempt at characterization of histologic subtypes.

F González-Crussi, M P Upton, H S Maurer.   

Abstract

This is a clinicopathologic study summarizing the experience with hepatoblastomas at Children's Memorial Hospital of Chicago between 1954 and 1981. Of 21 patients studied, 13 (61.9%) died. Three major histologic epithelial patterns were identified: fetal, embryonal, and macrotrabecular. The first two may represent different stages of cytodifferentiation of hepatoblastoma cells. The macrotrabecular type had features similar to hepatocellular carcinoma of adults, from which distinction was difficult; this type pursued an aggressive clinical course. The fetal type exhibited advanced differentiation, and two cases in this category survived after surgery only; local extrahepatic dissemination was present in other cases of the fetal type. Mixed epithelial and mesenchymal tumors constituted only 23% of this series, and none contained rhabdomyoblastic elements. Although modern chemotherapy may alter the course of this disease, the small size of this series precluded definite statements in this regard. Only patients in whom the tumor was completely excised as primary treatment became long-term survivors.

Entities:  

Mesh:

Year:  1982        PMID: 6295193

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

Review 1.  A case of hepatoblastoma occurring in an adult.

Authors:  K Sugino; K Dohi; T Matsuyama; T Asahara; M Yamamoto
Journal:  Jpn J Surg       Date:  1989-07

2.  Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.

Authors:  Marcio H Malogolowkin; Howard M Katzenstein; Rebecka L Meyers; Mark D Krailo; Jon M Rowland; Joel Haas; Milton J Finegold
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

3.  Hepatocarcinomas, cholangiocarcinomas, and hepatoblastomas produced by chemically transformed cultured rat liver epithelial cells. A light- and electron-microscopic analysis.

Authors:  M S Tsao; J W Grisham
Journal:  Am J Pathol       Date:  1987-04       Impact factor: 4.307

4.  Combination chemotherapy for unresectable hepatoblastoma in children.

Authors:  S Ogita; K Tokiwa; T Takahashi; S Imashuku; T Sawada
Journal:  Jpn J Surg       Date:  1987-01

5.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

6.  Abdominal, retroperitoneal and sacrococcygeal tumours of the newborn and the very young infant. Report from the Kiel Paediatric Tumour Registry.

Authors:  D Harms; D Schmidt; I Leuschner
Journal:  Eur J Pediatr       Date:  1989-08       Impact factor: 3.183

7.  Liver transplantation for hepatoblastoma in a child with congenital absence of the portal vein.

Authors:  J W Barton; M S Keller
Journal:  Pediatr Radiol       Date:  1989

8.  Liver transplantation for hepatoblastoma. The American experience.

Authors:  B Koneru; M W Flye; R W Busuttil; B W Shaw; M I Lorber; J C Emond; M Kalayoglu; D K Freese; T E Starzl
Journal:  Ann Surg       Date:  1991-02       Impact factor: 12.969

9.  Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors.

Authors:  Angela D Trobaugh-Lotrario; Gail E Tomlinson; Milton J Finegold; Lia Gore; James H Feusner
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

10.  Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.

Authors:  Marcio H Malogolowkin; Howard M Katzenstein; Mark Krailo; Zhengjia Chen; John J Quinn; Marleta Reynolds; Jorge A Ortega
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.